DEA Telehealth Extension Runs Out December 31
DEA's rule letting PMHNPs prescribe controlled substances by video with no in-person visit ends December 31, 2026. A permanent rule is in White House review.
Published
Key takeaways
- The deadline: the fourth temporary extension runs January 1 to December 31, 2026. After that, the Ryan Haight Act's in-person rule applies again to new patients unless DEA acts.
- What DEA is doing: its final special registration for telemedicine rule went to White House regulatory review on August 25, 2026, according to two health law firms tracking it.
- What the proposal said: a board-certified psychiatric NP would have qualified for the advanced registration needed to prescribe Schedule II drugs like stimulants by telehealth.
- As of November 5, 2026: no final rule and no fifth extension had been published in the Federal Register.
The DEA telehealth extension that lets a PMHNP prescribe controlled substances to a patient they've never seen in person ends at the end of December 31, 2026. Unless DEA publishes a permanent rule or a fifth extension before then, the Ryan Haight Act's in-person requirement comes back on January 1, 2027 for new telehealth patients. The permanent rule, a special registration for telemedicine, has been in White House review since August 25, 2026. Here's what the law requires, what DEA proposed, and what it means for the telehealth jobs you'll be interviewing for.
What the Ryan Haight Act Requires
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is the federal law behind all of this. DEA's 2025 proposal recounts why it exists: Ryan Haight was 17 when he bought prescription opioids online without ever being seen by the prescriber, and he died at 18. Under it, a practitioner can prescribe a controlled substance remotely only after at least one in-person medical evaluation of that patient. Once that one in-person visit has happened, the Act's remote-prescribing limits no longer apply to that practitioner and patient, so an established patient can be managed by video afterward.
The Act carves out seven categories that count as the "practice of telemedicine" and are exempt from the in-person rule. One of them is a special registration that DEA was supposed to create by regulation. In its January 2025 proposal, DEA said it had permitted telemedicine under only two of the seven. The temporary rules are what have filled the gap since 2020.
How DEA Got to a Fourth Extension
In March 2020, at the start of the COVID-19 public health emergency, DEA used its emergency authority to let any DEA-registered practitioner prescribe Schedule II to V drugs by telemedicine without an in-person visit. Since then:
| Date | What happened |
|---|---|
| March 2023 | DEA proposed permanent rules and drew 38,369 public comments |
| May 2023 | First temporary extension, through November 11, 2023 |
| October 2023 | Second extension, through December 31, 2024 |
| November 19, 2024 | Third extension, through December 31, 2025 |
| January 17, 2025 | Special registration proposed; buprenorphine and VA rules finalized |
| December 31, 2025 | Fourth extension, through December 31, 2026 |
| August 25, 2026 | Final special registration rule sent to White House review |
DEA has acted at the last minute before: the fourth extension was published on the last day of 2025. In that notice, DEA described the date the flexibilities lapse as the "telemedicine cliff" and quoted how much prescribing sits on it. A stakeholder summarized unpublished data reviewed by Epic, Johns Hopkins, and Stanford: of about 44.6 million controlled-substance prescriptions across 258 organizations in 2024, more than 7 million, roughly 16 percent, were written without a prior in-person evaluation.
What Happens on January 1, 2027 If Nothing Changes
The difference between new and established patients is the part to understand. A patient you, personally, have already evaluated in person isn't affected, because the Ryan Haight Act's limits stop applying once that visit has happened. The rule bites on new patients seen only by video. For them, you'd need an in-person evaluation before prescribing a controlled substance, unless one of the Act's other exceptions applies. Treating opioid use disorder with buprenorphine has its own permanent path, covered below.
For a telehealth company built on remote prescribing, that's a business problem. For you as a new graduate, it's mostly a question about how your employer will get new patients evaluated, and what that means for your schedule.
What the Special Registration Proposal Would Mean for PMHNPs
DEA proposed the special registration on January 17, 2025. The final version went to the Office of Information and Regulatory Affairs for review on August 25, 2026, as reported by McDermott Will & Schulte and Frier Levitt. Its text isn't public, so the final rule may differ. The 2025 proposal is the best guide to what's coming, and it had four parts that matter to you:
- Two tiers for clinicians. A Telemedicine Prescribing Registration would cover Schedule III to V drugs. An Advanced Telemedicine Prescribing Registration would add Schedule II, which includes most ADHD stimulants. The advanced tier was limited to certain specialists: psychiatrists, hospice, palliative care, long-term care, and pediatric physicians, neurologists, and mid-level practitioners board certified in treating psychiatric or psychological disorders. A PMHNP with board certification fits that last group, which is one more reason the board exam matters.
- A cap on Schedule II by telehealth. Telehealth Schedule II prescriptions would have to stay under 50% of the clinician's total Schedule II prescriptions in a month. A fully remote practice prescribing stimulants would fail that test.
- State registrations. You'd need a state telemedicine registration for every state your patients are in, on top of your state license.
- Identity and database checks. Before prescribing, you'd verify the patient's identity and check prescription drug monitoring program data in the patient's state, your state, and any state with a data-sharing agreement with them, moving to a nationwide check after three years.
The proposed fees were $888 for the special registration, on a three-year cycle, and $50 for each state registration. A separate platform registration was proposed for online telemedicine companies that dispense controlled substances.
Buprenorphine Has Its Own Permanent Rule
Opioid use disorder treatment doesn't depend on the extension. DEA and HHS finalized "Expansion of Buprenorphine Treatment via Telemedicine Encounter" on January 17, 2025, and after a delay it took effect on December 31, 2025. Under it, a practitioner can prescribe Schedule III to V medications approved for opioid use disorder by telemedicine, including audio-only, after reviewing the prescription drug monitoring program data for the state the patient is in. The first round can cover up to a six-month supply, split across several prescriptions. After that, further prescriptions need either another form of telemedicine allowed by law or an in-person evaluation, and the pharmacist has to verify the patient's identity before filling. A companion rule covers continuity of care for Veterans Affairs patients.
The extension notice also says a prescriber covered by these rules can still use the looser temporary flexibilities while they last, because the temporary rule imposes fewer requirements.
What This Doesn't Change
Federal telemedicine rules sit on top of state law, not instead of it. Your state still decides whether you can prescribe controlled substances at all, which schedules, and whether you need a collaborating physician. Our state-by-state guide to NP prescriptive authority covers that layer. And Medicare's separate telehealth rules, which decide what Medicare pays for, run on a different clock: Medicare's in-person requirement is delayed to January 1, 2028.
What This Means for PMHNP Students
If you're in school now, this affects how telehealth employers will let you prescribe once you're licensed. Controlled medications come up regularly in psychiatric practice: ADHD stimulants, benzodiazepines, some sleep medications. Under the temporary rules, an employer can start those by video. Under a special registration like the 2025 proposal, you'd likely need board certification and an advanced registration for stimulants, a registration for every state you see patients in, and enough in-person prescribing to stay under the Schedule II cap. If ADHD care is what you want to do, read whether a PMHNP can prescribe Adderall alongside this. When you interview for telehealth roles in 2027, ask how the employer handles controlled-substance prescribing for new patients, whether it offers in-person visits, and who pays for any added DEA registrations.
More PMHNP News
- HHS Finalizes HIPAA Privacy Rule Changes: 15-Day Records Deadline, No Change for Psychotherapy Notes Regulation · November 21, 2026
- DEA Raises Adderall and Ritalin Quotas as the Shortage Drags On Telehealth & Prescribing · November 14, 2026
- Medicare Telehealth Extension Keeps the In-Person Rule Off Until 2028 Telehealth & Prescribing · November 5, 2026
Questions About This Story
Can a PMHNP prescribe controlled substances by telehealth right now?+
What is the Ryan Haight Act?+
Will my existing telehealth patients be affected on January 1, 2027?+
Could a PMHNP prescribe Adderall by telehealth under special registration?+
Does this affect non-controlled psychiatric medications?+
Sources
Primary sources are the agency, board, or organization that made the change. We read each one on the date shown.
- [1] DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register document 2025-24123 (December 31, 2025) Primary Verified November 5, 2026
- [2] DEA and HHS, Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, Federal Register document 2025-01099 (January 17, 2025) Primary Verified November 5, 2026
- [3] DEA and HHS, Expansion of Buprenorphine Treatment via Telemedicine Encounter, final rule, Federal Register document 2025-01049 (January 17, 2025) Primary Verified November 5, 2026
- [4] DEA and HHS, delay of effective date to December 31, 2025, Federal Register document 2025-05007 (March 24, 2025) Primary Verified November 5, 2026
- [5] McDermott Will & Schulte, DEA Appears Close to Finalizing Telemedicine Special Registration Verified November 5, 2026
- [6] Frier Levitt, DEA Telemedicine Special Registration Final Rule Reaches White House Review (October 27, 2026) Verified November 5, 2026